Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
03
11
2021
accepted:
28
12
2021
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
The introduction of new and often shorter tuberculosis (TB) drug regimens affects the cost of TB programmes. We modelled drug purchase and import costs for 20-month, 9-month and 4- to 6-month TB drug regimens based on 2016-2020 treatment numbers from a TB programme in Karakalpakstan, Uzbekistan, and 2021 Global Drug Facility prices. On average, 2225±374 (±sd) people per year started TB treatment, 30±2.1% of whom were diagnosed with drug-resistant forms of TB. Transitioning from a 6-month to a 4-month drug-susceptible (DS)-TB drug regimen increased the TB programme's annual DS-TB drug cost from USD 65±10 K to USD 357±56 K (p<0.001) and its drug import cost from USD 6.4±1.0 K to USD 9.3±1.4 K (p=0.008). Transitioning from a 20-month all-oral multidrug-resistant (MDR)-TB drug regimen to a 9-month MDR-TB drug regimen with an injectable antibiotic decreased the TB programme's annual MDR-TB drug cost from USD 1336±265 K to USD 266±53 K (p<0.001) and had no significant effect on the drug import cost (USD 28±5.5 K Introducing new and shorter TB drug regimens could increase the cost of TB programmes with low drug resistance rates and decrease the cost of TB programmes with high drug resistance rates.
Sections du résumé
Background
UNASSIGNED
The introduction of new and often shorter tuberculosis (TB) drug regimens affects the cost of TB programmes.
Methods
UNASSIGNED
We modelled drug purchase and import costs for 20-month, 9-month and 4- to 6-month TB drug regimens based on 2016-2020 treatment numbers from a TB programme in Karakalpakstan, Uzbekistan, and 2021 Global Drug Facility prices.
Results
UNASSIGNED
On average, 2225±374 (±sd) people per year started TB treatment, 30±2.1% of whom were diagnosed with drug-resistant forms of TB. Transitioning from a 6-month to a 4-month drug-susceptible (DS)-TB drug regimen increased the TB programme's annual DS-TB drug cost from USD 65±10 K to USD 357±56 K (p<0.001) and its drug import cost from USD 6.4±1.0 K to USD 9.3±1.4 K (p=0.008). Transitioning from a 20-month all-oral multidrug-resistant (MDR)-TB drug regimen to a 9-month MDR-TB drug regimen with an injectable antibiotic decreased the TB programme's annual MDR-TB drug cost from USD 1336±265 K to USD 266±53 K (p<0.001) and had no significant effect on the drug import cost (USD 28±5.5 K
Conclusion
UNASSIGNED
Introducing new and shorter TB drug regimens could increase the cost of TB programmes with low drug resistance rates and decrease the cost of TB programmes with high drug resistance rates.
Identifiants
pubmed: 35350276
doi: 10.1183/23120541.00622-2021
pii: 00622-2021
pmc: PMC8943289
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2022.
Déclaration de conflit d'intérêts
Conflict of interest: S. Kohler and N. Paul have consulted for Médecins Sans Frontières (MSF). N. Sitali works as a Medical Operations Manager for MSF. J. Achar worked as tuberculosis medical advisor for the MSF Manson Unit.
Références
Cost Eff Resour Alloc. 2003 Feb 26;1(1):1
pubmed: 12773220
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
PLoS Med. 2006 Sep;3(9):e352
pubmed: 16968123
PLoS One. 2020 Dec 1;15(12):e0241065
pubmed: 33259492
Lancet. 2020 5-11 Sep;396(10252):693-724
pubmed: 32334655
ERJ Open Res. 2021 Feb 08;7(1):
pubmed: 33585652
Pharmacoeconomics. 2015 Sep;33(9):939-55
pubmed: 25939501
Euro Surveill. 2013 Oct 17;18(42):
pubmed: 24176581
N Engl J Med. 2021 May 6;384(18):1705-1718
pubmed: 33951360
Lancet. 2002 Jun 8;359(9322):1980-9
pubmed: 12076553
Lancet. 2013 Oct 19;382(9901):1373-9
pubmed: 23726162
Int J Tuberc Lung Dis. 2014 Dec;18(12):1390-5
pubmed: 25517802
Eur Respir J. 2012 Jul;40(1):133-42
pubmed: 22362862
Health Econ Rev. 2016 Dec;6(1):28
pubmed: 27406392
PLoS One. 2020 Dec 3;15(12):e0243428
pubmed: 33270800
Int J Environ Res Public Health. 2021 Apr 27;18(9):
pubmed: 33925705